Key points are not available for this paper at this time.
Key Points Myeloma patients progressing on BCMA-targeted therapy can maintain BCMA expression and still respond to different BCMA-targeted therapy. These observations suggest this patient population could be included in ongoing BCMA-targeted therapy trials.
Cohen et al. (Mon,) studied this question.